A study of elsunersen for children with SCN2A-related epilepsy
Part of Brain & nervous system clinical trials.
This trial tests an experimental drug called elsunersen in children with a specific type of epilepsy caused by changes in the SCN2A gene. It aims to see if the drug can reduce seizures and be safe for children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed change (called a gain-of-function variant) in the SCN2A gene.
- Your seizures must have started before you were 3 months old.
- You must have at least 4 countable motor seizures in a 28-day period before the study starts.
- You cannot have any other known genetic changes that could explain your epilepsy.
- You must not have used any experimental drugs, devices, or gene therapy in the last 30 days or 5 half-lives (whichever is longer).
- If you can become pregnant, you must not be pregnant or breastfeeding, and you must not plan to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study aims to better understand SCN1A-related epilepsies by following patients over time. Researchers hope to learn more about how the condition progresses to help develop future treatments.
This early-phase study tests how safe ETX101 is and whether it can help reduce seizures in young children with Dravet syndrome caused by an SCN1A gene change. It mainly enrolls infants and children with a specific type of seizure history and genetic result.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Hear when a new Epileptic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.